Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche’s Avastin approved for additional indication in Europe
The approval was based on data from the pivotal Phase III Avoren trial, which showed that patients with advanced renal cell cancer (RCC) who received Avastin in combination
The approval was based on data from the pivotal Phase III Avoren trial, which showed that patients with advanced renal cell cancer (RCC) who received Avastin in combination
The clinical Phase III program will consist of several clinical studies that will be conducted at investigational sites around the world. Based on the positive clinical phase II
With this agreement, Eisai will assume exclusive rights for development and marketing of these products in Japan and in the Euro-Asia countries and region where the products are
In the preclinical studies, PTC299 was administered to mice harboring established human breast tumor xenografts. In these studies, PTC299 monotherapy significantly decreased human tumor and plasma VEGF levels,
Under the agreement, Idera has agreed to exclusively license the therapeutic oncology applications, excluding their use with cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. In
The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study to evaluate the safety and tolerability as well as the pharmacokinetic profile of ACR343
The results show that patients receiving 150mg of PRX-03140 orally once daily as monotherapy achieved a mean 5.7 point improvement on the Alzheimer’s Disease Assessment Scale cognitive subscale
The payment is the second of two triggered by the December 2006 FDA approval of Elestrin, a treatment for reducing hot flashes associated with menopause, and brings the
Under the new agreement, Confirma will offer program consultation, experienced applications training, customizable educational courses, and marketing and reimbursement consultation to GE Healthcare customers with CADstream, the standard
Under the terms of the agreement, Affymetrix will pay approximately $75 million in cash to acquire USB. The transaction is expected to close in the first quarter of